Abstract
The 3-D structure of the human mTOR kinase domain was modeled based on the crystal structure of PI3Kγ using comparative modeling methods, and the ATP-binding site of mTOR was characterized. The mTOR kinase 3-D model structure is similar to the structure of the PI3Kγ kinase domain, and exhibits great similarity to PI3Kγ at the active site of the kinase. Pharmacophore generation, the docking of mTOR inhibitors, and molecular dynamics (MD) simulations of mTOR–inhibitor docked complexes were carried out in this work. The best pharmacophore model generated from 27 ATP-competitive mTOR inhibitors comprised two hydrogen-bond acceptors, one aromatic ring, and one hydrophobic feature. These 27 inhibitors were docked into the ATP-binding site comprising the DFG motif, and the interactions in each protein–inhibitor complex were characterized. Mapping the pharmacophore model onto the docked inhibitors explained the specificity of the features of the pharmacophore and how they were arranged inside the active site of mTOR kinase. MD studies revealed important structural features, such as the large hydrophobic pocket “HP” and hydrophilic pocket “A1,” and the solvent-exposed hydrophilic pocket “A2” at the active site of mTOR. Our results provide structural models of mTOR–inhibitor complexes and clues that should aid in the design of better mTOR kinase inhibitors.
Similar content being viewed by others
References
Sarbassov DD, Ali SM, Sabatini DM (2005) Curr Opin Cell Biol 17:596–603
Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A, Hall MN (2004) Nat Cell Biol 6:1122–1128
Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2002) Cell 110:163–175
Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K (2002) Cell 110:177–189
Yonezawa K, Tokunaga C, Oshiro N, Yoshino K (2004) Biochem Biophys Res Commun 313:437–441
Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2004) Curr Biol 14:1296–1302
Guertin DA, Sabatini DM (2005) Trends Mol Med 11:353–361
Presneau N, Shalaby A, Idowu B, Gikas P, Cannon SR, Gout I, Diss T, Tirabosco R, Flanagan AM (2009) Br J Cancer 100:1406–1414
Saunders RN, Metcalfe MS, Nicholson ML (2001) Kidney Int 59:3–16
Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, Travis R, Sausville EA, Houghton PJ (2001) Clin Cancer Res 7:1758–1764
Hidalgo M, Rowinsky EK (2000) Oncogene 19:6680–6686
Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW (2001) Circulation 104:2007–2011
Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, García-Echeverría C (2008) Mol Cancer Ther 7:1851–1863
Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud F, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ (2008) J Med Chem 51:5522–5532
Chau CH, Wang W, Figg WD (2008) Cancer Biol Ther 7:1386–1387
Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP (2008) J Clin Invest 118:3065–3074
Yuan TL, Cantley LC (2008) Oncogene 27:5497–5510
Menear KA, Gomez S, Malagu K, Bailey C, Blackburn K, Cockcroft XL, Ewen S, Fundo A, Le Gall A, Hermann G, Sebastian L, Sunose M, Presnot T, Torode E, Hickson I, Martin NM, Smith GC, Pike KG (2009) Bioorg Med Chem Lett 19:5898–5901
García-Martínez JM, Moran J, Clarke RG, Gray A, Cosulich SC, Chresta CM, Alessi DR (2009) Biochem J 421:29–42
Nowak P, Cole DC, Brooijmans N, Bursavich MG, Curran KJ, Ellingboe JW, Gibbons JJ, Hollander I, Hu Y, Kaplan J, Malwitz DJ, Toral-Barza L, Verheijen JC, Zask A, Zhang WG, Yu K (2009) J Med Chem 52:7081–7089
Zask A, Verheijen JC, Curran K, Kaplan J, Richard DJ, Nowak P, Malwitz DJ, Brooijmans N, Bard J, Svenson K, Lucas J, Toral-Barza L, Zhang WG, Hollander I, Gibbons JJ, Abraham RT, Ayral-Kaloustian S, Mansour TS, Yu K (2009) J Med Chem 52:5013–5016
Thompson JD, Higgins DG, Gibson TJ (1994) Nucleic Acids Res 22:4673–4680
Sali A, Potterton L, Yuan F, Van Vlijmen H, Karplus M (1995) Proteins 23:318–326
Hess B, Kutzner C, Van der Spoel D, Lindahl E (2008) J Chem Theor Comput 4:435–447
Van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ (2005) J Comput Chem 26:1701–1718
Jones G, Willett P, Glen RC (1995) J Mol Biol 245:43–53
Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) J Mol Biol 267:727–748
Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, Ayral-Kaloustian S, Mansour TS, Gibbons JJ, Abraham RT, Nowak P, Zask A (2009) Cancer Res 69:6232–6240
Schüttelkopf AW, van Aalten DM (2004) Acta Crystallogr D 60:1355–1363
Li J, Zhu X, Yang C, Shi R (2010) J Mol Model 16:789–798
Lemkul JA, Allen WJ, Bevan DR (2010) J Chem Inf Model 50:2221–2235
Nosé S (1984) Mol Phys 52:255–268
Hoover WG (1985) Phys Rev A 31:1695–1697
Parrinello M, Rahman A (1981) J Appl Phys 52:7182–7190
Nośe S, Klein ML (1983) Mol Phys 50:1055–1076
Laskowski RA, MacArthur MW, Moss DS, Thornton JM (1993) J App Cryst 26:283–291
Ramachandran GN, Ramakrishnan C, Sasisekharan V (1963) J Mol Biol 7:95–99
Acknowledgments
The authors thank the Department of Science and Technology (DST), India, for financial support (no. SR/S5/MBD-05/2007). The authors thank the Centre for Modelling Simulation and Design (CMSD), University of Hyderabad, Hyderabad, and the Centre for Development of Advanced Computing (CDAC), Pune, India, for providing access to their computational facilities. KT thanks the Council of Scientific and Industrial Research (CSIR), New Delhi, for research fellowship.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Fig. 1a
(DOC 109 kb)
Supplementary Fig. 1b
(DOC 260 kb)
Supplementary Fig. 1c
(DOC 174 kb)
Supplementary Fig. 1d
(DOC 41 kb)
Rights and permissions
About this article
Cite this article
Tanneeru, K., Guruprasad, L. Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors. J Mol Model 18, 1611–1624 (2012). https://doi.org/10.1007/s00894-011-1184-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00894-011-1184-3